---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-088024"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:43:51.294361+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences reports FY 2022 net loss of $13.9M; advancing FB-102 toward clinic in late 2023/early 2024

## Summary
- Net loss of $13.9M ($0.80/sh) vs $21.7M ($1.55/sh) in FY 2021; cash and equivalents $41.1M at year-end.
- R&D expenses decreased to $5.6M from $13.9M due to termination of FB-401; G&A rose to $8.3M.
- Lead candidate FB-102 for autoimmune diseases expected to enter clinic in late 2023 or early 2024.
- Board appointed David Gryska (former CFO of Incyte and Celgene) in January 2023.

## SEC filing metadata
- accession: 0001193125-23-088024
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/0001193125-23-088024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/d475905d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-088024
- JSON: https://secwatch.observer/filing/0001193125-23-088024.json
- Plain text: https://secwatch.observer/filing/0001193125-23-088024.txt

## Key facts
- Earnings Releases
  Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2022 results: net income Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D, EPS net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively..
  - Period: the fourth quarter and fiscal year ended December 31, 2022
  - Net income: Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D
  - EPS: net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively.
  - Result: reported results
  source text: On March 31, 2023, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/0001193125-23-088024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.